Submit a manuscript Sign up for article alerts Contact us Support


Latest comments

Co-corresponding author: Liang Cao (Xiang Hu, 15 October 2014)

Liang Cao and Xiang Hu are listed as Co-corresponding author read full comment

Comment on: Cao et al. Journal of Translational Medicine, 12:267

Affiliation Correction (Xiaofang Xing, 27 March 2014)

The affiliation should be "Key Laboratory of Carcinogenesis and Translational Research, Beijing Cancer Hospital & Institute, Beijng, China". Meanwhile, there is a correction article being processed to formally note the title "Key Laboratory of Carcinogenesis  and Translational Research" as an affiliation. read full comment

Comment on: Xing et al. Journal of Translational Medicine, 11:309

concordant results (Manuel Valladares-Ayerbes, 17 September 2012)

I suggest to read the following article Dharanija Madhavan, et al.
Their results are in agreement with ours in breast cancer. read full comment

Comment on: Valladares-Ayerbes et al. Journal of Translational Medicine, 10:186

correction (Hajime Isomoto, 11 April 2011)

Please change as follows.
miR-205 induces an epithelial-mesenchymal transition (EMT)-like phenotype through regulating zinc finger E-box binding homeobox 2 (ZEB2) expression
should be corrected into
'Inhibition of miR-205 induces an epithelial-mesenchymal transition (EMT)-like phenotype through regulating zinc finger E-box binding homeobox 2 (ZEB2) expression'

The miR-205 _expression levels did not differ among the histological subclasses of ESCC differentiation (Figure 5C), albeit those in invasive ESCC with poor differentiation were significantly lower than in intraepithelial ESCC (Figure 5D).
should be corrected into
'The miR-205 _expression levels did not differ among the histological subclasses of ESCC differentiation (Figure... read full comment

Comment on: Matsushima et al. Journal of Translational Medicine, 9:30

Transfection tutorial (Rachel Oliver, 18 March 2011)

Here’s a video that will help increase transfection efficiency. read full comment

Comment on: Rubie et al. Journal of Translational Medicine, 9:22

Neutrophil ATP related parameters in chronic fatigue syndrome (Norman Booth, 28 February 2011)

Norman E Booth, Mansfield College, University of Oxford
Sarah Myhill, Sarah Myhill Ltd
John McLaren-Howard, Acumen Medical Ltd

It is gratifying to see experts in the biomedical field turn their attention to the devastating illness Chronic Fatigue Syndrome (CFS/ME), as exemplified in the above paper by Vermeulen et al [1]. Further studies of the postexertional malaise following exercise, either physical or mental, are extremely important because this malaise is the most characteristic and disabling symptom of CFS/ME. Also, in spite of many studies, there is inadequate understanding of the biochemical processes which lead to this malaise.

In 2009, we published our findings from an audit where we compared deficiencies in the provision of ATP in... read full comment

Comment on: Vermeulen et al. Journal of Translational Medicine, 8:93

Additional information on the collaborative groups involved in the Taskforce (Lisa Butterfield, 25 February 2009)

The iSBTc has brought together experts from multiple stakeholders who have been focusing significant effort in this area including the United States Food and Drug Administration (FDA); the National Cancer Institute (NCI); the National Institutes of Health (NIH); members from industry; and partnering organizations such as the Biotherapy Development Association (BDA), Association for Immunotherapy of Cancer (CIMT), Cancer Vaccine Consortium (CVC), Nordic Center for Development of Antitumour Vaccines (NCV-network), the Italian Network for Tumor Biotherapy (NIBIT) as well as academic experts in the field of immunologic biomarker development and standardization. The planned October 2009 workshop is unique in that it is meant to be an interactive exchange rather than merely a didactic exercise... read full comment

Comment on: Butterfield et al. Journal of Translational Medicine, 6:81

Further development of ADRS for TSE investigation (George Robin Barclay, 26 November 2007)

In the competing interests section of this paper we state that "Radar World Ltd participated on a voluntary basis out of scientific curiosity and is not currently developing a commercial interest in this field". For clarification, this does not mean that ADROK Ltd (formerly Radar World Ltd) have no further interest in this - far from it. They would be very interested in developing this technology further with suitable collaborators, and would invite an approach by anyone who might be interested in developing this for clinical (and/or veterinary) application. read full comment

Comment on: Fagge et al. Journal of Translational Medicine, 5:41

HIFU and potential immune response in cancer therapy (George Suarez, 05 November 2007)

We have been using HIFU in combination with autologous patient's Dendrite cell therapy for advanced prostate cancer with excellent outcomes. There is no doubt that the combination therapy holds great promise for advanced stage desease in prostate cancer, as well as potential other types of cancer. For more information visit read full comment

Comment on: Hu et al. Journal of Translational Medicine, 5:34

Thank you for choosing an Open Access Journal (Graham Steel, 16 September 2007)

I wish to publicly thank the Authors of this important Paper for choosing to publish this in an Open Access Journal.By making such Papers freely and widely available, I firmly believe will vastly speed up science/research in this regard.The speed in which this Paper was submitted, Peer Reviewed and published on the internet is a far cry from traditional business models.Moreover, with this Paper being immediately archived in PubMed and PubMed Central, this is extremely important and the way forward.I have already alerted many colleagues to this Paper. Without Open Access, I would simply not have been able to do so !!I sincerely hope that more and more Authors like these ones publish via Open Access and ensure that their work is deposited in an Institutional Repository.Kind... read full comment

Comment on: Fagge et al. Journal of Translational Medicine, 5:41

Our findings conclude that immune suppression is not needed for a successful transplant of cord blood (Norman Ende, 02 May 2007)

In essence, we strongly agree with Dr. Thomas Ichim’s January 30, 2007 review article “Cord Blood in regenerative medicine: do we need immune suppression?”. Since 2000, our laboratory has produced positive clinical responses after administering unaltered cord blood mononuclear cells to animal models including Amyotrophic Lateral Sclerosis 1, 2, Huntington’s Disease3, Diabetes I and II4-6, Alzheimer’s 7and Parkinson’s8, Lupus9, Prostate Cancer12, and Atherosclerosis13 all without the use of immunosuppressant. In our initial research, outlined in our 2000 ALS paper2, we used radiation, but found immunosuppressant was unnecessary10. All the animal models of human diseases, treated only with cord blood mononuclear cells, without immunosuppressant, have... read full comment

Comment on: Riordan et al. Journal of Translational Medicine, 5:8

Lyme Disease and co infections/CFS/antibiotics (kim marott, 19 September 2006)

Our daughter presented at 14 with severe headaches, joint pain, muscle and tendon pain,severe fatigue, mental disturbances, depression for 5 years. Was diagnosed with CFS and Fibromyalgia with no relief...eventually diagnosed with bipolar disorder. After The Western Blot blood test given at age 19 she showed accutely positive for Lyme Disease with Bartonella and Mycoplasma bacterial co-infections...One of the antibiotics that is recommended is Azithromycin. COULD CFS BE CAUSED BY THE LYME SPIROCHETTE AND NO ONE IS TESTING FOR IT? read full comment

Comment on: Vermeulen et al. Journal of Translational Medicine, 4:34

Modeling Niche construction behaviour in Ovarian cancer (Peter R Main, 02 January 2006)

Wang et al provide an extensive and logical review of inflammatory and thrombotic controls possibly operant via angiogensis and other systems, evident in ovarian cancer and its peritoneal response.Such a system has features of "niche construction" in complex adaptive systems (CAS) useful in ecosystems modeling. In such systems there appears a major problem of dealing with dynamic adaptive diversity (ie rapid mutation that alters the crosstalk being used by the cancer to control host cell lines). Adaptation of tumour to therapeutic challenges is a well established mode of failure in therapies.This diversity of a CAS subject to control intervention, needs to be formally considered, when planning the early clinical extension of their work to interventions of thrombotic or inflammatory... read full comment

Comment on: Wang et al. Journal of Translational Medicine, 3:25

Inhibitor of immune efficiency (Zorica Juranic, 03 November 2004)

The failure of the antitumor effect of cancer vaccines even when they are completely elicited in some of cancer (melanoma) patients is frequently observed .This could be due to the enhanced presence of some proteins which could inhibit lytic cytotoxic action of perforin. One of such proteins could be calreticulin.Calreticulin exerts plenty of functions which among many others include lectin-like chaperoning, calcium storage and signaling, modulation of gene expression, of cell adhesion, enhancement of phagocytosis of C1q, inhibition of angiogenesis and tumoral growth, and it inhibits C1q-dependent complement activation(1). In higher organisms, calreticulin is present in almost all cell types, except erythrocytes. It is present in a wide spectrum of sub cellular compartments, and it is... read full comment

Comment on: Chiriva-Internati et al. Journal of Translational Medicine, 2:26

PAI-1 excess and decrease active MMPs impair monocyte migration in diabetes (Melvin Hayden, 10 December 2003)

Congratulations on an excellent article.In additon to increased bFGF and VEGF in diabetic peripheral monocytes, have you considered the elevation in PAI-1 levels as being implicated in the Vascular Paradox of diabetes: Accelerated angiogenesis and impaired arteriogenesis (collateral formation)?Excess PAI-1 would result in a decrease in Plasmin, which converts latent MMPs to active MMPs.If latent MMP activation is impaired then the extracellular matrix would not be digested and thus impair the migration of the monocyte within the extracellular matrix [1]. 1. Hayden MR, Tyagi SC: Arteriogenesis: Angiogenesis within Unstable Atherosclerotic Plaque-- Interactions with Extracellular Matrix.Curr Interv Cardiol Rep. 2000 Aug;2(3):218-227 Thank you for your excellent article and I would... read full comment

Comment on: Panutsopulos et al. Journal of Translational Medicine, 1:6